Treatment of severe coagulopathy after gunshot injury to the head using recombinant activated factor VII

被引:18
作者
Aiyagari, V [1 ]
Menendez, JA
Diringer, MN
机构
[1] Univ Illinois, Dept Neurol & Rehabil, Chicago, IL 60612 USA
[2] Washington Univ, Sch Med, Dept Neurosurg, Neurol Neurosurg Intens Care Unit, St Louis, MO 63110 USA
关键词
coagulopathy; head injury; factor VII;
D O I
10.1016/j.jcrc.2005.02.004
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Purpose: Patients with severe penetrating head injury often have a coagulopathy that is difficult to correct. In this report, we describe 3 such patients who were treated with activated factor VII (FVIIa) to stop ongoing hemorrhage that was refractory to conventional treatment. Subjects and Methods: We treated 3 patients with severe head injury secondary to gunshot wounds to the head. All 3 patients had ongoing bleeding secondary to a severe consumptive coagulopathy that was refractory to treatment with fresh frozen plasma, platelets, and cryoprecipitate. Recombinant FVIIa was then administered to achieve hemostasis. Results: Administration of FVIIa (90-120 mu g/kg) was successful in rapidly achieving hemostasis and correcting abnormal laboratory parameters indicative of coagulopathy in all patients. Although all 3 patients died, control of bleeding made organ donation possible in 2 patients. Conclusion: In patients with a severe head injury and coagulopathy, use of FVIIa may help in correction of coagulopathy and decrease transfusion requirements. In patients where ongoing bleeding precludes the declaration of brain death, the use of this agent might help in achieving hemodynamic stability and preserve the possibility of organ donation. The ethical implications of using FVIIa in this situation are discussed. (c) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:176 / 179
页数:4
相关论文
共 20 条
[1]   The cost of allogeneic red blood cells -: a systematic review [J].
Amin, M ;
Fergusson, D ;
Aziz, A ;
Wilson, K ;
Coyle, D ;
Hébert, P .
TRANSFUSION MEDICINE, 2003, 13 (05) :275-285
[2]   Ongoing NovoSeven® trials [J].
Erhardtsen, E .
INTENSIVE CARE MEDICINE, 2002, 28 (Suppl 2) :S248-S255
[3]   Coagulofibrinolytic changes after isolated head injury are not different from those in trauma patients without head injury [J].
Gando, S ;
Nanzaki, S ;
Kemmotsu, O .
JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE, 1999, 46 (06) :1070-1076
[4]   Application of recombinant activated factor VII during surgery for a giant skull base hemangiopericytoma to achieve safe hemostasis - Case report [J].
Gerlach, R ;
Marquardt, G ;
Wissing, H ;
Scharrer, I ;
Raabe, A ;
Seifert, V .
JOURNAL OF NEUROSURGERY, 2002, 96 (05) :946-948
[5]   DEFIBRINATION AFTER BRAIN-TISSUE DESTRUCTION - SERIOUS COMPLICATION OF HEAD-INJURY [J].
GOODNIGHT, SH ;
KENOYER, G ;
RAPAPORT, SI ;
PATCH, MJ ;
LEE, JA ;
KURZE, T .
NEW ENGLAND JOURNAL OF MEDICINE, 1974, 290 (19) :1043-1047
[6]  
Hulka F, 1996, ARCH SURG-CHICAGO, V131, P923
[7]   CLINICOPATHOLOGICAL CORRELATIONS OF DISSEMINATED INTRAVASCULAR COAGULATION IN PATIENTS WITH HEAD-INJURY [J].
KAUFMAN, HH ;
HUI, KS ;
MATTSON, JC ;
BORIT, A ;
CHILDS, TL ;
HOOTS, WK ;
BERNSTEIN, DP ;
MAKELA, ME ;
WAGNER, KA ;
KAHAN, BD ;
GILDENBERG, PL .
NEUROSURGERY, 1984, 15 (01) :34-42
[8]   Treatment of traumatic bleeding with recombinant factor VIIa [J].
Kenet, G ;
Walden, R ;
Eldad, A ;
Martinowitz, U .
LANCET, 1999, 354 (9193) :1879-1879
[9]   Recombinant activated factor VII for adjunctive hemorrhage control in trauma [J].
Martinowitz, U ;
Kenet, G ;
Segal, E ;
Luboshitz, J ;
Lubetsky, A ;
Ingerslev, J ;
Lynn, M .
JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE, 2001, 51 (03) :431-438
[10]   Recombinant activated factor VII for cerebral injury-induced coagulopathy in pediatric patients - Report of three cases and review of the literature [J].
Morenski, JD ;
Tobias, JD ;
Jimenez, DF .
JOURNAL OF NEUROSURGERY, 2003, 98 (03) :611-616